Continuing versus Withholding renin angiotensin aldosterone system antagonists before non-cardiac surgery: A protocol of a systematic review and meta-analysis

##plugins.themes.academic_pro.article.sidebar##

Published Aug 1, 2025
https://doi.org/10.62438/tunismed.v103i8.5662
Download
pdf
Vol. 103 No. 8 (2025): Tunis Med Aug 2025

##plugins.themes.academic_pro.article.main##

Mohamed Ali Chaouch
Department of Visceral and Digestive Surgery, Fattouma Bourguiba University Hospital, Monastir, Tunisia
Faten Haddad
Department of anesthesia and intensive care, Mongi Slim Hospital,La Marsa, Faculty of medicine of Tunis,,University of Tunis El Manar, Tunis, Tunisia.
Emna Kammoun
Department of anesthesia and intensive care, Mongi Slim Hospital,La Marsa, Faculty of medicine of Tunis,,University of Tunis El Manar, Tunis, Tunisia.
Henri Clautiaux
Department of Anesthesiology, Montreuil Intercommunal Hospital Center, France
Mohamed Aziz Daghmouri
Department of Anesthesiology, Montreuil Intercommunal Hospital Center, France

Abstract

Introduction: Perioperative use of ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) has been linked to early postinduction hypotension requiring vasopressor use under general anesthesia, potentially leading to complications like acute renal injury, myocardial injury, or stroke. However, the relationship between perioperative ACEI/ARB use and major morbidity remains uncertain.


Aim: This meta-analysis assessed the differences between the continuation or discontinuation of ACE inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) therapy during the perioperative period and hemodynamical instability, mortality, and major morbidity outcomes.


Methods: The protocol was registered in the PROSPERO database (ID: CRD42024519162). Literature searches of electronic databases and manual searches on the Medline, Embase, Scopus, and Web of Science databases up to August 30, 2024, will be performed. Case-control studies, cohort studies, non-randomized controlled trials, and randomized controlled trials (RCTs) involving adult patients aged over 18 years, who were chronically using ACEIs or ARBs due to chronic hypertension, undergoing non-cardiac surgery, where ACEIs or ARB therapy was either withheld or continued less than 10 hours before surgery will be included.   


The primary outcome will be the incidence of intraoperative hypotension. Secondary outcomes will be the intraoperative use of vasoactive agent (incidence, dose of ephedrine (mg) and dose of phenylephrine (ng)), the incidence of severe hypotension, hospital length of stay, intraoperative and postoperative hypertension, the incidence of acute kidney injury, 30-day postoperative all-cause mortality and incidence of major cardio-cerebral events.


Conclusion: The results of this systematic review and meta-analysis should ...( abstract truncated at 250 words).


 

Keywords:

Angiotensin-converting enzyme inhibitors, renin-angiotensin system inhibitor, continuing, with holding, pre-operative, non-cardiac surgery, meta-analysis, systematic review

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Roshanov PS, Rochwerg B, Patel A, Salehian O, Duceppe E, Belley-Côté EP, et al. Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology. 2017 Jan;126(1):16–27.
  2. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022 Oct 14;43(39):3826–924.
  3. Salim F, Khan F, Nasir M, Ali R, Iqbal A, Raza A. Frequency of Intraoperative Hypotension After the Induction of Anesthesia in Hypertensive Patients with Preoperative Angiotensin-converting Enzyme Inhibitors. Cureus. 12(1):e6614.
  4. Rosenman DJ, McDonald FS, Ebbert JO, Erwin PJ, LaBella M, Montori VM. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period. J Hosp Med. 2008 Jul;3(4):319–25.
  5. Coriat P, Richer C, Douraki T, Gomez C, Hendricks K, Giudicelli JF, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology. 1994 Aug;81(2):299–307.
  6. Brabant SM, Bertrand M, Eyraud D, Darmon PL, Coriat P. The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists. Anesth Analg. 1999 Dec;89(6):1388–92.
  7. Comfere T, Sprung J, Kumar MM, Draper M, Wilson DP, Williams BA, et al. Angiotensin system inhibitors in a general surgical population. Anesth Analg. 2005 Mar;100(3):636–44.
  8. Pigott DW, Nagle C, Allman K, Westaby S, Evans RD. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth. 1999 Nov;83(5):715–20.
  9. Foucrier A, Rodseth R, Aissaoui M, Ibanes C, Goarin JP, Landais P, et al. The long-term impact of early cardiovascular therapy intensification for postoperative troponin elevation after major vascular surgery. Anesth Analg. 2014 Nov;119(5):1053–63.
  10. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021 Mar 29;372:n160.
  11. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. bmj. 2017;358.
  12. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898.
  13. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2020 Jun 15]. Available from: https://handbook-5-1.cochrane.org/
  14. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005 Apr 20;5(1):13.
  15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557–60.
  16. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–34.
  17. Copas J, Shi JQ. Meta-analysis, funnel plots and sensitivity analysis. Biostatistics. 2000;1(3):247–62.
  18. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011 Apr;64(4):401–6.